Evidence map›Paper›PMID 26241709›Full record

ArticleMedical science monitor : international medical journal of experimental and clinical research2015

High VEGF-D and Low MMP-2 Serum Levels Predict Nodal-Positive Disease in Invasive Bladder Cancer.

Tobias Benoit, Etienne X Keller, Pirmin Wolfsgruber, Thomas Hermanns, Michele Günthart, Irina Banzola, Tullio Sulser, Maurizio Provenzano, Cédric Poyet

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical science monitor : international medical journal of experimental and clinical research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Tobias BenoitDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Etienne X KellerDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Pirmin WolfsgruberDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Thomas HermannsDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Michele GünthartDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Irina BanzolaDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Tullio SulserDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Maurizio ProvenzanoDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
Cédric PoyetDepartment of Urology, University Hospital, University of Zürich, Zürich, Switzerland.
University of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo investigate stromal variables including angiogenesis, lymphangiogenesis, and matrix metalloproteinase (MMP) in the serum of patients with urothelial carcinoma of the bladder (UCB) and to evaluate their association with histopathological characteristics and clinical outcome. MATERIAL AND

methodsProtein levels of vascular endothelial growth factors-A, -C, -D (VEGF-A/-C/-D), their receptors- VEGF-R2 and -R3 (VEGF-R2/-R3), and matrix metalloproteinases 2, -3, and -7 (MMP-2, MMP-3, MMP-7) were quantified in the blood serum samples of 71 patients with UCB before radical cystectomy (RC). Samples of patients with non-invasive UCB or no history of UCB were investigated as controls (n=20). Protein levels in the serum were measured using a flow cytometric cytokine assay.

resultsA positive association for VEGF-D (p<0.001) and an inverse association for MMP-2 (p=0.017) were observed in patients with positive lymph node (LN) status at the time of RC. VEGF-A (p<0.001), VEGF-C (p<0.001), MMP-2 (p<0.001), and MMP-7 (p=0.005) serum levels were different in serum of patients with invasive UCB compared with non-invasive UCB or healthy individuals. None of the serum markers were associated with disease progression.

conclusionsHigh VEGF-D and low MMP-2 serum levels predict LN metastasis in patients with UCB at the time of RC. VEGF-A, VEGF-C, MMP-2, and MMP-7 serum levels varied significantly between invasive and non-invasive disease as well as in comparison with healthy individuals. Clinical implementation of these marker serum measurements may be valuable to select high-risk patients with more invasive or nodal-positive disease.

Indexed as

AgedAged, 80 and overBiomarkers, TumorCase-Control StudiesFemaleHumansLymphatic MetastasisMaleMatrix Metalloproteinase 2Middle AgedNeoplasm InvasivenessPredictive Value of TestsPrognosisUrinary Bladder NeoplasmsVascular Endothelial Growth Factor DBiomarkers, TumorMatrix Metalloproteinase 2MMP2 protein, humanVascular Endothelial Growth Factor DVEGFD protein, human

Identifiers

PMID26241709
PMCPMC4530984
OpenAlexW1935319686

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.